Angle plc (AGL)

Overview

ANGLE plc operates within the medical diagnostic industry, focusing on advancing cancer diagnostics across various regions including the United Kingdom, Europe, North America, and globally. Initiated in 1994 and based in Guildford, the United Kingdom, ANGLE plc specializes in the development of innovative cancer diagnostic products. The company's standout offering, the Parsortix PC1 system, epitomizes their commitment to improving cancer diagnostics. This system is designed for the efficient capture and collection of intact circulating tumour cells (CTCs) from the blood of patients suffering from metastatic breast cancer, facilitating their subsequent analysis. Additionally, ANGLE plc has established a strategic partnership with Bio View Ltd aimed at creating a novel assay kit tailored for breast cancer, specifically targeting the human epidermal growth factor receptor 2. This collaboration highlights ANGLE plc's dedication to enhancing cancer diagnostic techniques through productive partnerships.

Products and Services

• Parsortix PC1 System: A groundbreaking medical device engineered for the capture and harvest of intact circulating tumour cells (CTCs) from the blood of patients with metastatic breast cancer. The collected cells can then undergo further analysis according to user-defined criteria, showcasing this system’s utility in cancer diagnostics and research.
• Portrait+ CTC Staining Kit: This convenient, ready-to-use laboratory kit is geared towards the identification, characterization, and enumeration of both epithelial and mesenchymal transition CTCs. It boasts high analytical sensitivity and specificity, making it an essential tool for researchers in the field.
• CellKeep Slide: This technology stands as a novel method for the harvesting of CTCs. Designed for compatibility and ease of use, the CellKeep Slide enhances the accuracy and reliability of capturing these cells from patient blood samples.
• Laboratory Services:
  • Enumeration of epithelial and mesenchymal CTC populations: Offering detailed analysis and counting of various CTC types within patient samples.
  • Portrait Flex: An immunofluorescence assay specially formulated for the identification of epithelial, mesenchymal, and epithelial-to-mesenchymal transition cells.
  • DNA Damage Response: A service designed to assess the efficacy of treatment protocols based on the DNA repair capabilities of CTCs.
  • Portrait PD-L1: Evaluates CTCs for the presence of PD-L1, aiding in the selection of appropriate immune-oncology therapies.
  • Custom CTC Assays: Tailored assays developed based on the specific needs and requirements of researchers, providing flexibility and precision in cancer diagnostics.